Academic literature on the topic 'Epatitis C'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Epatitis C.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Epatitis C"
Martins, Paulo N. "Transplantation of L ivers F rom V iremic H epatitis C V irus– P ositive D onors I nto H epatitis C V irus– N egative R ecipients." Hepatology 68, no. 4 (October 2018): 1656. http://dx.doi.org/10.1002/hep.30106.
Full textMubarak, Ghassan, and Richard Ferstenberg. "The E fficacy of T enofivir to P revent P erinatal T ransmission in C hronic H epatitis B M others. A C linical P erspective." Hepatology 68, no. 4 (October 2018): 1658. http://dx.doi.org/10.1002/hep.30138.
Full textGuyader, D. "Epatite cronica virale C." EMC - AKOS - Trattato di Medicina 17, no. 2 (June 2015): 1–10. http://dx.doi.org/10.1016/s1634-7358(15)70635-2.
Full textHoussel‐Debry, Pauline, Audrey Coilly, Claire Fougerou‐Leurent, Caroline Jezequel, Christophe Duvoux, Victor Ledinghen, Sylvie Radenne, et al. "12 W eeks of a R ibavirin‐ F ree S ofosbuvir and N onstructural P rotein 5 A I nhibitor R egimen I s E nough to T reat R ecurrence of H epatitis C A fter L iver T ransplantation." Hepatology 68, no. 4 (October 2018): 1277–87. http://dx.doi.org/10.1002/hep.29918.
Full textLombardi, Marco. "Il punto su epatite B e C in dialisi: riflessioni sulla contumacia dei pazienti." Giornale di Clinica Nefrologica e Dialisi 26, no. 4 (June 30, 2014): 321–25. http://dx.doi.org/10.33393/gcnd.2014.931.
Full textStratta, P., C. Musetti, E. Turello, E. Lazzarich, D. Palmieri, T. Cena, and C. Magnani. "L'infezione da epatite C peggiora la prognosi dopo il trapianto di rene: esperienza di 400 trapiantati in un unico Centro." Giornale di Tecniche Nefrologiche e Dialitiche 18, no. 3 (July 2006): 68–71. http://dx.doi.org/10.1177/039493620601800320.
Full textStratta, P., C. Musetti, E. Turello, E. Lazzarich, D. Palmieri, T. Cena, and C. Magnani. "L'infezione da epatite C peggiora la prognosi dopo il trapianto di rene: esperienza di 400 trapiantati in un unico Centro." Giornale di Clinica Nefrologica e Dialisi 18, no. 3 (July 1, 2006): 68–71. http://dx.doi.org/10.33393/gcnd.2006.1570.
Full textRefolo, Pietro, Dario Sacchini, Filippo Rumi, Americo Cicchetti, and Antonio G. Spagnolo. "“Farmaci insostenibili” e giustizia intergenerazionale in Sanità." Medicina e Morale 68, no. 4 (December 20, 2019): 411–22. http://dx.doi.org/10.4081/mem.2019.596.
Full textNava, Felice A., Lucia Trevisi, and Alfio Lucchini. "Costo-beneficio del trattamento con i farmaci antivirali ad azione diretta nei consumatori di sostanze con epatite C: una valutazione del percorso di point of care." MISSION, no. 55 (July 2021): 8–17. http://dx.doi.org/10.3280/mis55-2020oa12158.
Full textSullivan, Sean D., A. Craxì, A. Alberti, G. Giuliani, C. De Carli, N. Wintfeld, K. K. Patel, and J. Green. "Rapporto costo-efficacia della terapia peginterferone α-2a + ribavirina in confronto a interferone α-2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati." PharmacoEconomics Italian Research Articles 6, no. 2 (July 2004): 105–14. http://dx.doi.org/10.1007/bf03320628.
Full textDissertations / Theses on the topic "Epatitis C"
Cecília, Cavalcanti de Albuquerque Ana. "Prevalência e fatores de risco para hepatite C em pacientes hemodialisados de uma unidade de diálise de Recife/PE." Universidade Federal de Pernambuco, 2003. https://repositorio.ufpe.br/handle/123456789/7353.
Full textCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
A infecção pelo vírus da hepatite C (HCV) é um importante problema de saúde pública em todo mundo. Esta infecção acomete cerca de 3% da população mundial. No Brasil, existe um percentual de positividade para o HCV de 1,2%, baseado em dados originários dos exames de triagem de doações de sangue. A principal via de transmissão é a parenteral e por isso as populações mais atingidas são politransfundidos, usuários de drogas injetáveis e pacientes renais crônicos que realizam tratamento de hemodiálise. A alta prevalência da infecção pelo HCV nesses pacientes vêm sendo relatada por vários autores em todo o mundo. No Brasil, estudos têm mostrado que pacientes hemodialisados têm uma prevalência de anti-HCV de 12,5% - 65%. Os objetivos deste estudo foram estimar a prevalência da infecção pelo HCV em um centro de diálise da grande Recife; associar a positividade para o HCV em relação a alguns fatores de risco; conhecer os genótipos do HCV circulantes neste centro e estimar a presença de pacientes com o HCV RNA e anti-HCV não reagente. Foram analisados 250 pacientes com idade variando de 17 a 92 anos e de ambos os sexos. Dados epidemiológicos desses pacientes foram obtidos para a determinação dos fatores de riscos para esta infecção. A pesquisa de anticorpos foi realizada pelo ELISA de 3ª geração e para a detecção do HCV RNA foi utilizada a técnica de RT/PCR. Do produto amplificado foi realizada a técnica do seqüenciamento da região 5 NCR do genoma viral. Foi observada uma prevalência de 8,4% (21/250) da infecção e os genótipos: 1a (42%), 3a (37%) e 1b (21%). Em relação aos fatores de riscos, como o tempo de hemodiálise, número e período das transfusões sangüíneas e/ou hemoderivados, foi encontrada uma associação estatisticamente significante (p< 0,05). A prevalência encontrada foi baixa em relação a outros estudos Brasileiros. Observou-se uma excelente concordância do ELISA com a PCR (K=0,946). A homogeneidade dos genótipos reflete uma transmissão nosocomial, porém são necessários estudos retrospectivos e prospectivos nesse centro para avaliar o período em que os pacientes adquirem esta infecção
Castro, Gleusa de. "Análise histológica comparativa de biópsias hepáticas de pacientes com hepatite C crônica, co-infectados pelo HIV-1, realizadas antes e após o tratamento da hepatite C." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/17/17138/tde-18012007-182909/.
Full textHuman immunodeficiency virus (HIV) is known to be able to modify the natural history of HCV infection, accelerating the progression of hepatic fibrosis and the consequent evolution to cirrhosis. Treatment with interferon-alpha can lead to improved hepatic histology, reducing inflammation and fibrosis, especially in patients who present a sustained virologic response. The impact of treatment on histological evolution in patients who do not respond to treatment of hepatitis C is a controversial matter. Objectives: To evaluate in patients with chronic hepatitis C co-infected with HIV the impact of treatment of hepatitis C on the modifications of the parameters indicative of fibrosis and of inflammatory activity in liver biopsies obtained before and after treatment of hepatitis C. Methods: Twenty-six patients co-infected with HCV and HIV-1 were submitted to a liver biopsy before and, on average, 25.2 months after the end of treatment of hepatitis C. Fragments of the liver biopsy were compared before and after treatment regarding the following parameters: histological activity index (HAI) and grade of fibrosis (Knodell); intensity of collagen deposition (picrosirius staining), and grade of stellate cell activation (labeling with smooth muscle alpha-actin). The post- and pretreatment ratios of these histological variables were related to the result of the quantitative HCV-RNA test (RT-PCR-AMPLICOR?) during the 24th week of treatment, to the duration of treatment of hepatitis C and to the time interval between the discontinuation of treatment and the control biopsy. The relationship between possible factors of the virologic response and the histological response was evaluated and correlations between the various histological parameters were calculated. Results: The histological parameters evaluated in a global manner were similar in the pre- and post-treatment biopsies. The post-pretreatment ratios for all parameters evaluated in the liver biopsies were significantly reduced in patients who were negative for HCV RNA during the 24th week of treatment. The histological parameters were similar in the groups with different durations of treatment (? 24 weeks and > 24 weeks), except for ?-positive stellate hepatic cells, which were improved in the group with a more prolonged treatment. The time interval between the end of treatment and the control biopsy did not affect the histological improvement. In logistic regression analysis, the improvement of the histological parameters was found to be associated with a negative result of HCV RNA during the 24th week of treatment. There was a significant correlation between all histological parameters evaluated. Conclusions: When evaluated as a whole, the patients showed similar values for their histological parameters in the pre- and post-treatment biopsies. However, when histological improvement was defined as the maintenance or improvement of the histological parameters evaluated individually, a substantial part of the study population was found to present histological improvement. The beneficial effect of treatment seemed to be related to the control of HCV viremia during treatment and was also observed in patients who did not sustain the virologic response after the discontinuation of the medications. These findings lead us to assume that the reduction of HCV viremia causes a reduction of hepatic inflammation and fibrosis, as well as a reduction of the state of activation of stellate hepatic cells even in cases in which there is no sustained virologic response. The results of the present study suggest that treatment of hepatitis C can modify the natural history of the course of chronic hepatitis in patients co-infected with HIV.
de, Ruvo Nicola <1966>. "Ricerca della tolleranza clinica e recidiva di Epatite C nel trapianto di fegato: effetti a lungo termine dell'induzione con anticorpi policlonali anti-timociti." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2007. http://amsdottorato.unibo.it/265/.
Full textCorradi, Francesco <1972>. "Ruolo dell'elastometria pulsata monodimensionale ad ultrasuoni (fibroscan) nella stadiazione della fibrosi epatica in pazienti sottoposti a trapianto ortotopico di fegato con recidiva di epatite C." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2007. http://amsdottorato.unibo.it/577/.
Full textBrener, Loren Psychology Faculty of Science UNSW. "Implicit and explicit attitudes of health care workers and their injecting drug using clients with hepatitis C: is this related to treatment experiences?" 2007. http://handle.unsw.edu.au/1959.4/40603.
Full textBooks on the topic "Epatitis C"
Epatite C: Gestione e Trattamento in Svizzera. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 2017.
Find full text